Healthcare / Drug Manufacturers - GeneralUpdated 2026-05-10 22:07 UTC

BCBA/AMGN stock hub

BCBA/AMGN has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BCBA/AMGNis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

249.3T

Buenos Aires Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

BCBA/AMGN

In the news

Latest news · BCBA/AMGN

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E14.6

P25 14.1P50 17.9P75 19.4

Trailing P/E23.1

P25 25P50 30P75 39

ROE101.3

P25 6.8P50 15.6P75 45.1

ROIC19.1

P25 9P50 19.1P75 21.2

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BCBA/AMGN market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

228

Groups with data

Currency

USD

Showing 228 of 228 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	AR
Employees	31,500
Employees Change	1,300%
Employees Change Percent	4.87
Enterprise value	ARS 312.4T
Exchange	Buenos Aires Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Drug Manufacturers - General
Last refreshed	2026-05-10
Market cap	ARS 249.3T
Price	ARS 16,440
Price currency	ARS
Rev Per Employee	1,632,379,044.89x
Sector	Healthcare
Sic	2836
Symbol	bcba/AMGN
Website	https://www.amgen.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	4.32%
EV Earnings	28.99x
EV/EBIT	18.47x
EV/EBITDA	13.06x
EV/FCF	26.3x
EV/Sales	6.03x
FCF yield	4.76%
Forward P/E	14.61x
P/B ratio	19.64x
P/E ratio	23.14x
P/S ratio	4.85x
PE Ratio10 Y	25.07x
PE Ratio3 Y	28.82x
PE Ratio5 Y	25.59x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	32.63%
EBITDA Margin	45.45%
FCF margin	23.1%
Gross margin	71.44%
Gross Profit	ARS 36.7T
Gross Profit Growth	12.82%
Gross Profit Growth Q	10.41%
Gross Profit Growth3 Y	10.66%
Gross Profit Growth5 Y	6.92%
Net Income	ARS 10.8T
Net Income Growth	31.47%
Net Income Growth Q	5.15%
Net Income Growth3 Y	-0.5%
Net Income Growth5 Y	1.94%
Pretax Margin	24.41%
Profit Margin	20.96%
Profit Per Employee	ARS 342.1M
ROA	8.35
Roa5y	8.22
ROCE	17.98
ROE	101.3
Roe5y	101.8
ROIC	19.05
Roic5y	20.52

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	57.05%
Cagr3y	68.63%
Cagr5y	67.37%
Div CAGR10	80.65%
Div CAGR3	120.28%
Div CAGR5	92.37%
EPS Growth	31.3
EPS Growth Q	4.38
EPS Growth3 Y	-0.8
EPS Growth5 Y	3.54
FCF Growth	-21.24%
FCF Growth Q	50.71%
FCF Growth3 Y	4.51%
FCF Growth5 Y	-2.65%
OCF Growth	-11.78%
OCF Growth Q	57.37%
OCF Growth10 Y	0.57%
OCF Growth3 Y	7.65%
OCF Growth5 Y	0.55%
Revenue Growth	9.07x
Revenue Growth Q	5.76x
Revenue Growth3 Y	12.43x
Revenue Growth5 Y	8.14x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	ARS 0.41
Assets	ARS 127.8T
Cash	ARS 16.6T
Current Assets	ARS 44T
Current Liabilities	ARS 34.9T
Debt	ARS 79.2T
Debt EBITDA	ARS 3.34
Debt Equity	ARS 6.24
Debt FCF	ARS 6.67
Equity	ARS 12.7T
Interest Coverage	3.92
Liabilities	ARS 115.1T
Long Term Assets	ARS 83.8T
Long Term Liabilities	ARS 80.2T
Net Cash	ARS -62.6T
Net Cash By Market Cap	ARS -25.09
Net Debt EBITDA	ARS 2.68
Net Debt Equity	ARS 4.93
Net Debt FCF	ARS 5.27
Tangible Book Value	ARS -42.6T
Tangible Book Value Per Share	ARS -79,003
WACC	6.16

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.26
Inventory Turnover	1.65
Net Working Capital	ARS -111.9B
Quick ratio	0.85
Working Capital	ARS 9T
Working Capital Turnover	ARS 9,850

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.09%
Dividend Growth	43.15%
Dividend Growth Years	15%
Dividend per share	ARS 275
Dividend Years	16
Dividend Yield	1.67%
Ex Div Date	2026-02-13
Last Dividend	ARS 75.99
Payout Frequency	Quarterly
Payout Ratio	66.71%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	57%
200-day SMA	15,832
3Y total return	379.64%
50-day SMA	17,404.4
50-day SMA vs 200-day SMA	50over200
5Y total return	1,212.72%
All Time High	19,280
All Time High Change	-14.73%
All Time High Date	2026-02-27
All Time Low	273.7
All Time Low Change	5,907.3%
All Time Low Date	2019-07-31
ATR	403.7
Beta	0.44
Ch YTD	-1.38
High	16,510
High52	19,280
High52 Date	2026-02-27
High52ch	-14.73%
Low	16,270
Low52	10,050
Low52 Date	2025-05-14
Low52ch	63.58%
Ma50ch	-5.54%
Price vs 200-day SMA	3.84%
RSI	42.77
RSI Monthly	61.25
RSI Weekly	48.1
Sharpe ratio	1.22x
Sortino ratio	1.98
Total Return	1.58%
Tr YTD	-0.74
Tr1m	-2.32%
Tr1w	2.05%
Tr3m	-12.4%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	ARS 16.8T
Operating Income Growth	18.32
Operating Income Growth Q	24.43
Operating Income Growth3 Y	8.22
Operating Income Growth5 Y	5.8
Operating margin	32.63

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	538,255,159%
Net Borrowing	22,378,526,672
Shares Insiders	0.17%
Shares Institutions	81.87%
Shares Qo Q	0.18%
Shares Yo Y	0.09%
Short Ratio	4.77

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	ARS 11.2T
Average Volume	1,899.7x
Bv Per Share	23,524.4
CAPEX	ARS -3T
Ch1m	-2.32
Ch1w	2.05
Ch1y	53.65
Ch3m	-12.97
Ch3y	356.8
Ch5y	1,125
Ch6m	4.71
Change	1.29%
Change From Open	0.49
Close	16,230
Days Gap	0.8
Depreciation Amortization	6,674,395,579,924
Dollar Volume	47,791,080
Earnings Date	2026-04-30
EBIT	ARS 16.8T
EBITDA	ARS 23.4T
EPS	ARS 19,850
F Score	8
FCF	ARS 11.9T
FCF EV Yield	3.8x
Financing CF	-7,344,126,829,200
Fiscal Year End	December
Founded	1,980
Goodwill	26,118,537,942,058
Graham Number	3658.40012
Graham Upside	-77.75
Income Tax	ARS 1.8T
Investing CF	-3,055,908,304,400
Is Primary Listing	0
Last Earnings Date	2026-04-30
Last Report Date	2026-03-31
Last Split Date	2024-01-24
Last Split Type	Forward
Lynch Fair Value	ARS 3,553
Lynch Upside	-78.39
Ma150	16,732.5
Ma150ch	-1.75%
Ma20	16,884.5
Ma20ch	-2.63%
Net CF	4,459,526,223,600
Next Earnings Date	2026-08-04
Open	16,360
P FCF Ratio	20.99
P OCF Ratio	16.78
Payment Date	2026-03-06
Position In Range	70.83
Ppne	11,491,373,446,072
Price Date	2026-05-08
Price EBITDA	ARS 10.67
Relative Volume	1.66x
Revenue	51,419,939,914,000x
SBC By Revenue	1.3x
Share Based Comp	668,652,630,800
Tax By Revenue	3.46x
Tax Rate	14.16%
Tr6m	5.86%
Volume	2,907
Z Score	1.75

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

BCBA/AMGN dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+1.7%

$275 annual per share

Payout ratio

+66.7%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+92.4%

15 consecutive years of growth

Total shareholder yield

+1.6%

Next ex-dividend date: 2026-02-13

Performance

BCBA/AMGN stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BCBA/AMGN?

Insider, institutional, and short-interest positioning.

Institutional ownership

+81.9%

Share of float held by funds and institutions

Insider ownership

+0.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

BCBA/AMGN momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

42.8

Neutral momentum band

Price vs 200-day MA

+3.8%

50/200-day relationship not available

Beta (5Y)

0.43

Less volatile than the market

Sharpe ratio

1.22

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BCBA/AMGN

Hub-level FAQ points readers to the deeper analysis pages.

What is the current bcba/AMGN stock rating?

bcba/AMGN is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full bcba/AMGN analysis?

The full report lives at /stocks/bcba/AMGN/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for bcba/AMGN?

The latest report frames bcba/AMGN around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the bcba/AMGN page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.